Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,15 USD | -10,16% | -2,54% | +109,09% |
Omzet 2024 * | 7,5 mln. 7,04 mln. | Omzet 2025 * | 18,75 mln. 17,6 mln. | Marktkapitalisatie | 39,64 mln. 37,21 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -67 mln. -62,9 mln. | Nettowinst (verlies) 2025 * | -72 mln. -67,59 mln. | EV/omzet 2024 * | -20,9 x |
Nettoliquiditeiten 2024 * | 196 mln. 184 mln. | Nettoliquiditeiten 2025 * | 302 mln. 283 mln. | EV/omzet 2025 * | -14 x |
K/w-verhouding 2024 * |
-0,7
x | K/w-verhouding 2025 * |
-0,95
x | Werknemers | 73 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 68,09% |
Recentste transcriptie over Xilio Therapeutics, Inc.
1 dag | -10,16% | ||
1 week | -2,54% | ||
Lopende maand | +6,48% | ||
1 maand | +67,88% | ||
3 maanden | +69,39% | ||
6 maanden | -41,03% | ||
Lopend jaar | +109,09% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
René Russo
CEO | Chief Executive Officer | 49 | 22-05-19 |
Kevin Brennan
DFI | Director of Finance/CFO | 54 | - |
Chief Tech/Sci/R&D Officer | - | 01-10-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Clancy
CHM | Chairman | 62 | 23-07-20 |
Daniel Curran
BRD | Director/Board Member | 57 | 01-12-20 |
Tomas Jan Heyman
BRD | Director/Board Member | 68 | 15-09-22 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
19-04-24 | 1,15 | -10,16% | 339 700 |
18-04-24 | 1,28 | +4,07% | 154 329 |
17-04-24 | 1,23 | -5,38% | 438 797 |
16-04-24 | 1,3 | +3,17% | 325 034 |
15-04-24 | 1,26 | +6,78% | 268 821 |
uitgestelde koers Nasdaq, 19 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+109,09% | 39,64 mln. | |
-1,42% | 41,52 mld. | |
+42,15% | 39,9 mld. | |
+1,97% | 38,83 mld. | |
-14,19% | 26,05 mld. | |
+1,82% | 23,78 mld. | |
-24,55% | 18,26 mld. | |
-4,07% | 11,65 mld. | |
+21,36% | 11,53 mld. | |
+8,20% | 11,2 mld. |